Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat

Journal of Applied Physiology

Volumn 97, Issue 6, 2004, Pages 2228-2235

  Gong, Hui ^a   Wang, Yan Xia ^a   Zhu, Yi Zhun ^b   Wang, Wen Wei ^a   Wang, Ming Jie ^a   Yao, Tai ^a   Zhu, Yi Chun ^a  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cardiac myocyte; Double staining; GPR14; Inotropic effect; Urotensin II

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GPR14 PROTEIN; NEUROPEPTIDE; POLYCLONAL ANTIBODY; TROPONIN C; UNCLASSIFIED DRUG; UROTENSIN II;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FROZEN SECTION; HEART MUSCLE CELL; HEART PAPILLARY MUSCLE; HEART VENTRICLE CONTRACTILITY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INOTROPISM; LIGAND BINDING; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGE FACTORS; ANIMALS; BLOTTING, WESTERN; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PAPILLARY MUSCLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UROTENSINS; VENTRICULAR FUNCTION, LEFT;

EID: 9244248645     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00540.2004     Document Type: Article

References (32)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, and Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286, 1999.
2. Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, and Douglas SA. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val- Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 137: 449-458, 2002.
3. Bern HA, Pearson D, Larson BA, and Nishioka RS. Neurohormones from fish tails: the caudal neurosecretory system. "Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Harm Res 41: 533-552, 1985.
4. Bottrill FE, Douglas SA, Hiley CR, and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130: 1865-1870, 2000.
5. Conlon JM, Yano K, Waugh D, and Hazon N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool 275: 226-238, 1996.
6. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, and Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 91: 161-170, 1995.
7. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, and Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95: 15803-15808, 1998.
8. Croston GE, Olsson R, Currier EA, Burstein ES, Weiner D, Nash N, Severance D, Allenmark SG, Thunberg L, Ma JN, Mohell N, O'Dowd B, Brann MR, and Hacksell U. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-(dimethyl-amino)ethyl)isochroman-1-one (AC-7954). J Med Chem 45: 4950-4953, 2002.
9. Douglas SA and Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10: 229-237, 2000.
10. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, and Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131: 1262-1274, 2000.
11. Douglas SA, Tayara L, Ohlstein EH, Halawa N, and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359: 1990-1997, 2002.
12. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, and Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45: 1799-1805, 2002.
13. Gardiner SM, March JE, Kemp PA, Davenport AP, and Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132: 1625-1629, 2001.
14. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol 91: 205-212, 1987.
15. Gibson A, Wallace P, and Bern HA. Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen Comp Endocrinol 64: 435-439, 1986.
16. Gray GA, Jones MR, and Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 69: 175-180, 2001.
17. Grieco P, Carotenuto A, Campiglia P, Zampelli E, Patacchini R, Maggi CA, Novellino E, and Rovero P. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J Med Chem 45: 4391-4394, 2002.
18. Hassan GS, Chouiali F, Saito T, Hu F, Douglas SA, Ao Z, Willette RN, Ohlstein EH, and Giaid A. Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol 81: 125-128, 2003.
19. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF, and Caskey CT. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266: 174-178, 1999.
20. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, and Polland K. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130: 201-204, 2000.
21. Moore AF, Heiderstadt NT, Huang E, Howell NL, Wang ZQ, Siragy HM, and Carey RM. Selective inhibition of the renal angiotensin type 2 receptor increases blood pressure in conscious rats. Hypertension 37: 1285-1291, 2001.
22. Mori M, Sugo T, Abe M, Shimomura Y, Kurihara M, Kitada C, Kikuchi K, Shintani Y, Kurokawa T, Onda H, Nishimura O, and Fujino M. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor (GPR14). Biochem Biophys Res Commun 265: 123-129, 1999.
23. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckies SP, and Civelli O. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1: 383-385, 1999.
24. Rossowski WJ, Cheng BL, Taylor JE, Datta R, and Coy DH. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438: 159-170, 2002.
25. Russell FD, Molenaar P, and O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132: 5-9, 2001.
26. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, and Crumbley AJ. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102: 1944-1949, 2000.
27. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, and MacLean MR. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280: H925-H928, 2001.
28. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy. Circ Res 93: 246-253, 2003.
29. Wittenberg BA, White RL, Ginzberg RD, and Spray D. Effect of calcium on the dissociation of the mature rat heart into individual and paired myocytes: electrical properties of cell pairs. Circ Res 59: 143-150, 1986.
30. Zhang Y, Li J, Cao J, Chen J, Yang J, Zhang Z, Du J, and Tang C. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 16: 64-68, 2002.
31. Zhu YZ, Wang ZJ, Zhu YC, Zhang L, Oakley RME, Chung CW, Lim KW, Lee HS, Ozoux ML, Linz W, Bohm M, and Kostenis E. Urotensin II causes fatal circulatory collapse in anaesthesized cynomolgus monkeys in vivo: a 'vasoconstrictor' with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 286: H830-H836, 2004.
32. Zou Y, Nagai R, and Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 508: 57-60, 2001.